Fate Therapeutics, Inc. (FATE): Price and Financial Metrics

FATE POWR Grades

• Value is the dimension where FATE ranks best; there it ranks ahead of 80.78% of US stocks.
• The strongest trend for FATE is in Stability, which has been heading down over the past 177 days.
• FATE ranks lowest in Stability; there it ranks in the 1st percentile.

FATE Stock Summary

• Of note is the ratio of FATE THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 8.73% of US stocks have a lower such ratio.
• As for revenue growth, note that FATE's revenue has grown 72.44% over the past 12 months; that beats the revenue growth of 89.79% of US companies in our set.
• The volatility of FATE THERAPEUTICS INC's share price is greater than that of 94.33% US stocks with at least 200 days of trading history.
• If you're looking for stocks that are quantitatively similar to FATE THERAPEUTICS INC, a group of peers worth examining would be ARVN, DNLI, ATRA, XNCR, and RNA.
• Visit FATE's SEC page to see the company's official filings. To visit the company's web site, go to www.fatetherapeutics.com.

FATE Valuation Summary

• FATE's price/earnings ratio is -1.9; this is 108.19% lower than that of the median Healthcare stock.
• Over the past 115 months, FATE's price/earnings ratio has gone up 5.4.

Below are key valuation metrics over time for FATE.

FATE Growth Metrics

The 2 year price growth rate now stands at 1.56%.
• Its 5 year cash and equivalents growth rate is now at 142.06%.
• Its 5 year net cashflow from operations growth rate is now at -207.58%.

Over the past 49 months, FATE's revenue has gone up $64,907,000.

The table below shows FATE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	69.013	-243.112	-293.979
2022-06-30	68.257	-221.44	-253.724
2022-03-31	63.12	-200.387	-232.752
2021-12-31	55.846	-162.87	-212.151
2021-09-30	54.675	-113.241	-196.641
2021-06-30	48.008	-110.599	-212.017

FATE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• FATE has a Quality Grade of D, ranking ahead of 19.68% of graded US stocks.
• FATE's asset turnover comes in at 0.058 -- ranking 313th of 680 Pharmaceutical Products stocks.
• RMTI, SYBX, and PTE are the stocks whose asset turnover ratios are most correlated with FATE.

The table below shows FATE's key quality metrics over time.